Guardant reported 48% revenue growth, including 44,000 Shield screening tests, and raised full-year guidance for revenue to $1.31 billion at the midpoint, or 3.6% higher than the guidance given in February.
Guardant is a leader in liquid biopsy, has been a step ahead of the competition, and is making steady progress toward profitability around 2028.
Guardant’s Shield could face stiff competition if multicancer early-detection tests eventually achieve comparable sensitivity and pricing.
|
Metric
|
GH
|
ILMN
|
|---|---|---|
Price/Earnings (Normalized) | — | 31.42 |
Price/Book Value | — | 8.98 |
Price/Sales | 14.71 | 5.57 |
Price/Cash Flow | — | 19.14 |
|
Metric
|
GH
|
ILMN
|
|---|---|---|
Quick Ratio | 4.25 | 1.21 |
Current Ratio | 4.68 | 1.75 |
Interest Coverage | −104.66 | 11.20 |
|
Metric
|
GH
|
ILMN
|
|---|---|---|
Return on Assets (Normalized) | −14.32% | 13.27% |
Return on Equity (Normalized) | — | 33.85% |
Return on Invested Capital (Normalized) | −20.78% | 17.57% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Qkcggkyxr | Vjtj | $175B | |||
| Danaher Corp
DHR
| Jwlyjhjlj | Zdphh | $130B | |||
| IDEXX Laboratories Inc
IDXX
| Cdltnkpwd | Pjpfd | $44B | |||
| Agilent Technologies Inc
A
| Mznzrlttg | Fpmxr | $37B | |||
| Waters Corp
WAT
| Jphflld | Xnxbn | $36B | |||
| IQVIA Holdings Inc
IQV
| Mtvcmvyk | Smwrhp | $31B | |||
| Illumina Inc
ILMN
| Frkbfss | Lsdrb | $24B | |||
| Mettler-Toledo International Inc
MTD
| Jjhjwctsxj | Gzjkfg | $23B | |||
| Quest Diagnostics Inc
DGX
| Ytjstrk | Gcrwmk | $22B | |||
| Labcorp Holdings Inc
LH
| Tssvhxfzx | Xgzkq | $21B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
United States